Opendata, web and dolomites

TETHIS-SBS-CTC

TETHIS-SBS-CTC: An innovative diagnostic testing platform to identify and characterize circulating tumour cells (CTCs) in blood samples.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TETHIS-SBS-CTC project word cloud

Explore the words cloud of the TETHIS-SBS-CTC project. It provides you a very rough idea of what is the project "TETHIS-SBS-CTC" about.

liquid    finalise    adequately    diagnostics    tethis    combination    market    huge    million    enrichment    methodology    sectors    feasibility    earlier    once    pharma    decades    nanotechnology    ctcs    roi    biology    expecting    oncology    helps    marker    immobilize    chance    blood    death    sbs    tumour    creates    proteomic    rate    biopsy    cellular    clinical    preparation    validated    alternatives    environment    diagnostic    encloses    financial    58    settings    therapy    finished    reflection    biotech    cells    accounting    secure    aggression    time    circulating    smart    profits    led    expertise    turn    detection    worldwide    metastatic    perfect    total    realization    discovery       posing    cancer    cure    people    stage    commercial    platform    molecular    run    pilot    characterization    biosurface    capability    capture    15    deaths    diagnosed    conceived    hire    drug    70    standpoint    causes    culminating    monitoring    healthcare    gain    driving   

Project "TETHIS-SBS-CTC" data sheet

The following table provides information about the project.

Coordinator
TETHIS SPA 

Organization address
address: VIA DE GRASSI GIOVANNINO 11
city: MILANO
postcode: 20123
website: www.tethis-lab.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.tethis-lab.com/liquid-biopsy/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TETHIS SPA IT (MILANO) coordinator 50˙000.00

Map

 Project objective

Cancer is one of the most important causes of death worldwide, accounting for 8.8 million deaths. The rate of new cases is expected to rise by 70% in the next 2 decades, posing a huge challenge for the healthcare system. If diagnosed early and treated adequately, many cases would have a high chance of cure. This realization is driving the growth in the cancer diagnostics market. The detection and analysis of Circulating Tumour Cells (CTCs) encloses a huge potential for real-time monitoring of cancer cases. CTCs are considered a “diagnostic tumour marker” since they are the reflection of a metastatic aggression. We at TETHIS have developed a new diagnostic platform to characterize CTCs from liquid biopsy (i.e. blood). The combination of our expertise in nanotechnology and strong biology knowledge have led to the development of a Smart BioSurface (SBS) that creates a perfect environment to immobilize CTCs using a total capture approach. Compared to the state-of-the-art alternatives, our methodology does not require pre-enrichment or selection. Having validated this technology for cancer diagnostics at the pilot stage, this project is conceived to finalise the development and market preparation of this technology, culminating in a diagnostic platform for cellular, proteomic and molecular characterization of CTCs. The platform will have key applications, including diagnostics and monitoring in clinical settings, and drug discovery & therapy development in the pharma/biotech sectors. The Phase 1 of this project is dedicated to run a Feasibility Study that helps us evaluate the project from a technical, commercial and financial standpoint. Once the project is finished, we expect our platform to improve the diagnostic capability in the oncology sector, enabling earlier detection and better management. In turn, it will secure the growth for TETHIS, expecting to gain over €10 million in profits, hire 15 new people and reach a ROI of €2.58 from this project after 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TETHIS-SBS-CTC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TETHIS-SBS-CTC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More